Publicaciones en las que colabora con María Dolores Lozano Escario (19)

2021

  1. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

    Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201

  2. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  2. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

  3. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  4. Programmed death–ligand 1 expression on direct Pap-stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens

    Cancer Cytopathology, Vol. 127, Núm. 7, pp. 470-480

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

2015

  1. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

    Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236

  2. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations

    BMC Genomics, Vol. 16, Núm. 1

  3. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

    Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304

  4. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient

    International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115

2014

  1. Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  3. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients

    Clinica Chimica Acta, Vol. 429, pp. 168-174

  4. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

2009

  1. EUELC project: A multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

    European Respiratory Journal, Vol. 34, Núm. 6, pp. 1477-1486

  2. Large cell carcinoma of the lung: An endangered species?

    Applied Immunohistochemistry and Molecular Morphology, Vol. 17, Núm. 5, pp. 383-392